α1-酸性糖蛋白(a1AGP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Alpha-1-Acid Glycoprotein (a1AGP)
AGP1; a1-AGP; ORM1; OMD 1; Orosomucoid 1
- 編號(hào)SEA816Mu
- 物種Mus musculus (Mouse,小鼠) 相同的名稱(chēng),不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍62.5-4,000ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于24.5ng/mL.
- 樣本類(lèi)型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 2722 ¥ 3888 ¥ 17496 ¥ 33048 ¥ 272160
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
特異性
本試劑盒用于檢測(cè)α1-酸性糖蛋白(a1AGP),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的α1-酸性糖蛋白(a1AGP)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 79-97 | 86 |
EDTA plasma(n=5) | 78-99 | 80 |
heparin plasma(n=5) | 95-105 | 98 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的α1-酸性糖蛋白(a1AGP),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中α1-酸性糖蛋白(a1AGP)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 78-104% | 91-99% | 78-101% | 96-105% |
EDTA plasma(n=5) | 89-98% | 95-102% | 84-101% | 95-103% |
heparin plasma(n=5) | 96-104% | 94-102% | 86-101% | 80-92% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時(shí);
3. 吸棄,加檢測(cè)溶液A100µL,37°C孵育1小時(shí);
4. 洗板3次;
5. 加檢測(cè)溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分鐘;
8. 加終止液50µL,立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將α1-酸性糖蛋白(a1AGP)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的α1-酸性糖蛋白(a1AGP)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的α1-酸性糖蛋白(a1AGP)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的α1-酸性糖蛋白(a1AGP)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA816Mu01 | α1-酸性糖蛋白(a1AGP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA816Mu02 | α1-酸性糖蛋白(a1AGP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA816Mu01 | α1-酸性糖蛋白(a1AGP)多克隆抗體 | WB,IHC |
PAA816Mu02 | α1-酸性糖蛋白(a1AGP)多克隆抗體 | WB; IHC; ICC; IP. |
LAA816Mu81 | α1-酸性糖蛋白(a1AGP)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
LAA816Mu71 | α1-酸性糖蛋白(a1AGP)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
SEA816Mu | α1-酸性糖蛋白(a1AGP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA816Mu | α1-酸性糖蛋白(a1AGP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA816Mu01 | α1-酸性糖蛋白(a1AGP)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
J Reprod Dev.? | An Acute-phase Protein as a Regulator of Sperm Survival in the Bovine Oviduct: Alpha 1-acid-glycoprotein Impairs Neutrophil Phagocytosis of Sperm In Vitro [Pubmed:Pmc4219990] |
Molecular Reproduction and Development | Evidence for a novel, local acute-phase response in the bovine oviduct: Progesterone and lipopolysaccharide up-regulate alpha 1-acid-glycoprotein expression in epithelial cells in vitro [Pubmed:25123565] |
BMC Complementary and Alternative Medicine | Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study [Pubmed:25652121] |
PLoS One | Gut Microbial Dysbiosis May Predict Diarrhea and Fatigue in Patients Undergoing Pelvic Cancer Radiotherapy: A Pilot Study [PubMed: 25955845] |
Sci Rep.? | S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine [pmc:PMC4810364] |
Journal of Chromatography A | Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis [S0021967317311858] |
Scientific Reports | An autoregressive logistic model to predict the reciprocal effects of oviductal fluid components on in vitro spermophagy by neutrophils in cattle [pubmed:28667317] |
33 | Transcriptome Analysis Uncovers a Growth-Promoting Activity of Orosomucoid-1 on Hepatocytes. [pubmed:28927749] |
Brazilian Journal of Otorhinolaryngology | Inflammatory markers in palatine tonsils of children with obstructive sleep apnea syndrome [Pubmed: 30213594] |
BioRxiv | Proteome-wide characterization and biomarker identification of intracranial aneurysm [] |
The FEBS journal | Dramatically changed immune‐related molecules as early diagnostic biomarkers of non‐small cell lung cancer [Pubmed: 31482685] |
PLoS One | Effects of vaccination on acute-phase protein response in broiler chicken [Pubmed: 32191767] |
Indian Journal of Animal Sciences | Peripheral concentrations of metabolic and inflammatory indicators during transition period and their relationship with postpartum clinical endometritis in dairy?… [] |
A New Biomarker Tool for Risk Stratification in ?°De Novo?± Acute Heart Failure (OROME) [] |